bio today: thalia therapeutics

Timeline

Health & Bio Today: Thalia Therapeutics acquires AML RNA therapy firm in £2.75m-backed deal, Primary Health Properties, Verici Dx, Beximco Pharmaceuticals, Cambridge Cognition

21:18, 24 Jun 2026

More in Healthcare

The image captures a female researcher in a laboratory environment, engaged in oncological research at a dual-monitor workstation. She analyzes a printed figure against scientific data displayed on the screens, which include bioinformatics interfaces and a microscopy image showcasing stained tissue samples, while her workspace features organized laboratory tools like sample tubes and a notebook.

Pharma

Cavendish reiterates 'buy' on HUTCHMED with 436p target after 19% share-price slide

The broker sees the oncology-focused biopharma as clearly undervalued, with a catalyst-rich second half ahead.

09:56, 25 Jun 2026

Medtech & Diagnostics

Paraytec agrees heads of terms with US breath-tech firm VosBio to explore lung cancer detection

08:22, 25 Jun 2026

AIM & Small Cap

The Premarket Brief: easyJet rejects fourth Castlelake bid at £4.93bn, Advanced Medical Solutions, Time Finance, Clean Power Hydrogen, Serco

08:04, 25 Jun 2026

Biotech

Agronomics portfolio company Tropic buys banana propagation business Rahan Meristem for $20m

07:48, 25 Jun 2026

Pharma

ImmuPharma names Bachem as manufacturing partner for Kapiglucagon drug program

07:36, 25 Jun 2026

Pharma

Hutchmed's fanregratinib hits 42.5% response rate in bile duct cancer trial

07:33, 25 Jun 2026

Medtech & Diagnostics

H.B. Fuller to acquire Advanced Medical Solutions for £695m

07:31, 25 Jun 2026

Biotech

FDA clears single pivotal trial path for Avacta's AVA6000 in salivary gland cancer

07:28, 25 Jun 2026

Medtech & Diagnostics

Cambridge Cognition raises minimum £2.5m to fund regulatory clearances and platform development

07:36, 24 Jun 2026

Medtech & Diagnostics

Verici Dx clears New York lab certification to complete US nationwide coverage

07:36, 24 Jun 2026

Pharma

Beximco Pharma half-year profit surges 36% as domestic and export sales both accelerate

07:35, 24 Jun 2026

Timeline

Health & Bio Today: Thalia Therapeutics acquires AML RNA therapy firm in £2.75m-backed deal, Primary Health Properties, Verici Dx, Beximco Pharmaceuticals, Cambridge Cognition

More in Healthcare

Cavendish reiterates 'buy' on HUTCHMED with 436p target after 19% share-price slide

Paraytec agrees heads of terms with US breath-tech firm VosBio to explore lung cancer detection

The Premarket Brief: easyJet rejects fourth Castlelake bid at £4.93bn, Advanced Medical Solutions, Time Finance, Clean Power Hydrogen, Serco

Agronomics portfolio company Tropic buys banana propagation business Rahan Meristem for $20m

ImmuPharma names Bachem as manufacturing partner for Kapiglucagon drug program

Hutchmed's fanregratinib hits 42.5% response rate in bile duct cancer trial

H.B. Fuller to acquire Advanced Medical Solutions for £695m

FDA clears single pivotal trial path for Avacta's AVA6000 in salivary gland cancer

Cambridge Cognition raises minimum £2.5m to fund regulatory clearances and platform development

Verici Dx clears New York lab certification to complete US nationwide coverage

Beximco Pharma half-year profit surges 36% as domestic and export sales both accelerate

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer